Treatment of substance use disorders in schizophrenia

References

• Oorschot M, Lataster T, Thewissen V, Lardinois M, van Os J, Delespaul PA, Myin-Germeys I. Symptomatic remission in psychosis and real-life functioning. Brit J Psychiat 2012;201:215–220.
   PubMed Web of Science ®Google Scholar
• Spellman I, Riedel M, Schennach R, Seemuller F, Obermeier M, Musil R, Jager M, Schmaub M, Laux G, Pfeiffer H, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Maier W, Lemke MR, Ruther E, Klinberg S, Gastpar M, Moller HJ. One-year functional outcomes of naturalistically treated patients with schizophrenia. Psychiat Res 2012;198:378–385.
   PubMed Web of Science ®Google Scholar
• Corring DJ, Cook JV. Use of qualitative methods to explore the quality-of-life construct from a consumer perspective. Psychiat Serv 2007;58:240–244.
   PubMed Web of Science ®Google Scholar
• Gadelha A., Noto CS, de Jesus Mari J. Pharmacological treatment of schizophrenia. Int Rev Psychiatr 2012;24:489–498.
   PubMed Web of Science ®Google Scholar
• Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8–19.
   PubMed Web of Science ®Google Scholar
• Regier DA, Farmer ME, Rae DS, Locke BZ, Keither SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 1990;264:2511–2518.
   PubMed Web of Science ®Google Scholar
• Mueser KT, Bennett ME, Kushner MG. Epidemiology of substance abuse among persons with chronic mental disorders. In: A. Lehman and L. Dixon eds. Substance abuse disorders among persons with chronic mental illness. New York: Harwood Academic Publishers, 1995.
   Google Scholar
• Bennett ME, Peer J, Gjonbalaj-Marovic S. The Problem of Dual Diagnosis. In M. Hersen, Turner S, Beidel D, eds. Adult psychopathology and diagnosis. 7th ed. NY: John Wiley and Sons; 2014.
   Google Scholar
• Kerfoot KE, Rosenheck RA, Petrakis IL, Swartz MS, Keefe RS, McEvoy JP, Stroup TS, CATIE Investigators. Substance use and schizophrenia: adverse correlates in the CATIE study sample. Schizophr Res 2011;132:177–182. doi: 10.1016/j.schres.2011.07.032.
   PubMed Web of Science ®Google Scholar
• Casey DA, Rodriguez M, Northcott C, Vickar G, Shihabuddin L. Schizophrenia: medical illness, mortality, and aging. Int J Psychiatry Med 2011;41:245–251. doi: 10.2190/PM.41.3.c
   PubMed Web of Science ®Google Scholar
• Jeste DV, Wolkowitz OM, Palmer BW. Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia. Schizophr Bull 2011;37:451–455. doi: 10.1093/schbul/sbr026.
   PubMed Web of Science ®Google Scholar
• Dixon L, Dickerson F, Bellack A, Bennett M, Dickinson D, Goldberg R, Lehman A, Tenhula W, Calmes C, Pasillas R, Peer J, Kreyenbuhl J. The 2009 PORT Psychosocial Treatment Recommendations and Summary Statement. Schizophr Bull 2010;36:48–70.
   Google Scholar
• Tsuang JW, Eckman T, Marder S, Tucker D. Can risperidone reduce cocaine use in substance abusing schizophrenic patients? J Clin Psychopharmacol 2002;22:629–630.
   PubMed Web of Science ®Google Scholar
• Gerra G, Di Petta G, D’Amore A, Iannotta P, Bardicchia F, Falorni F, Coacci A, Strepparola G, Campione G, Lucchini A, Vedda G, Serio G, Manzato E, Antonioni M, Bertacca S, Moi G, Zaimovic A. Combination of olanzapine with opiod-agonists in the treatment of heroin-addicted patients with comorbid schizophrenia spectrum disorders. Clin Neuropharmacol 2007;30:127–135.
   PubMed Web of Science ®Google Scholar
• Lee ML, Dickson RA, Campbell M, Oliphant J, Gretton H, Dalby JT. Clozapine and substance abuse in patients with schizophrenia. Can J Psychiatry 1998;43:855–856.
   PubMed Web of Science ®Google Scholar
• Levin FR, Evans SM, Coomaraswammy S, Collins ED, Regent N, Kleber HD. Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study. Am J Drug Alcohol Abuse 1998; 24:343–360.
   PubMed Web of Science ®Google Scholar
• Buckley P, McCarthy M, Chapman P, Richman C, Yamamoto B. Clozapine treatment of comorbid substance abuse in patients with schizophrenia. Schizophr Res 1999;36:272.
   Web of Science ®Google Scholar
• Littrell KH, Petty RG, Hilligoss NM, Peabody CD, Johnson CD. Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat 2001;21:217–221.
   PubMed Web of Science ®Google Scholar
• Beresford TP, Clapp L, Martin B, Wiberg JL, Alfers J, Beresford HF. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 2005;25:363–366.
   PubMed Web of Science ®Google Scholar
• Potvin S, Stip E, Lipp O, Elie R, Mancini-Marie A, Demers M, Roy M, Bouchard R, Gendron A. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin 2006;22:1277–1285.
   PubMed Web of Science ®Google Scholar
• Sayers SL, Campbell EC, Kondrich J, Mann SC, Cornish J, O’Brien C, Caroff SN. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis 2005;193:379–386.
   PubMed Web of Science ®Google Scholar
• Smelson DA, Ziedonis D, Williams J, Losonczy MF, Williams J, Steinberg ML, Kaune M. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence. J Clin Psychopharmacol 2006;26:9–12.
   PubMed Web of Science ®Google Scholar
• Akerele E, Levin FR. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. Am J Addict 2007;16:260–268.
   PubMed Web of Science ®Google Scholar
• Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 2006;51:531–539.
   PubMed Web of Science ®Google Scholar
• Brunette MF, Dawson R, O’Keefe CD, Narasimhan M, Noordsy DL, Wojcik J, Green AI. A randomized trial of clozapine vs. other antipsychotics on cannabis use disorder in patients with schizophrenia. J Dual Diagn 2011;7:50–63.
   Google Scholar
• Schnell T, Koethe D, Krasnianski A, Gairing S, Schnell K, Daumann J, Gouzoulis-Mayfrank E. Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. Am J Addict 2014;23:308–312.
   PubMed Web of Science ®Google Scholar
• Miotto P, Preti A, Frezza M. Heroin and schizophrenia: subjective responses to abused drugs in dually diagnosed patients. J Clin Psychopharmacol 2001;21:111–113.
   PubMed Web of Science ®Google Scholar
• Gerra G, Leonardi C, D’Amore A, Strepparola G, Fagetti R, Assi C, Zaimovic A, Lucchini A. Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: a retrospective study. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:265–272.
   PubMed Web of Science ®Google Scholar
• Bruno A., Romeo VM, Pandolfo G, Scimeca G, Zoccali RA, Muscatello MRA. Aripiprazole plus topiramate in opioid-dependent patients with schizoaffective disorder: An 8-Week, open-label, uncontrolled, preliminary study. Substance Abuse 2014;35:119–121. doi: 10.1080/08897077.2013.814615.
   PubMed Web of Science ®Google Scholar
• Kern AM, Akerman SC, Nordstrom BR. Opiate dependence in schizophrenia: case presentation and literature review. J Dual Diagn 2014;10:52–57. doi:10.1080/15504263.2013.867199.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration, Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.
   Google Scholar
• Tek C, Srihari V, Tek E. Successful acamprosate treatment of alcohol dependence in schizophrenia. Schizophr Res 2008;106:373.
   PubMed Web of Science ®Google Scholar
• Mueser KT, Noordsy DL, Fox L, Wolfe R. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict 2003;12:242–252.
   PubMed Web of Science ®Google Scholar
• Kingsbury SJ, Salzman, C. Disulfiram in the treatment of alcoholic patients with schizophrenia. Hospital Community Psychiatry 1990;41:133–134.
   PubMedGoogle Scholar
• Batki SL, Dimmock J, Cornell M, Wade M, Carey K, Maisto S. Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders. Am J Addict 2007;16:253–259.
   PubMed Web of Science ®Google Scholar
• Petrakis IL, O’Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH; VA Naltrexone Study Collaboration Group. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology 2004;172:291–297.
   PubMed Web of Science ®Google Scholar
• Petrakias IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B, VA New England VISN 1 MIRECC Study Group. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry 2005;57:1128–1137.
   PubMed Web of Science ®Google Scholar
• Petrakis IL, Nich C, Ralevski E. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull 2006;32:644–654.
   Google Scholar
• Ralevski E, O’Brien E, Jane JS, Dean E, Dwan R, Petrakis I. Effects of acamprosate on cognition in a treatment study of patients with schizophrenia spectrum disorders and comorbid alcohol dependence. J Nerv Ment Dis 2011;199:499–505.
   PubMed Web of Science ®Google Scholar
• Meszaros ZS, Abdul-Malak Y, Dimmock JA, et al. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo controlled pilot trial. J Clin Psychopharmacol 2013;33:243–247.
   PubMed Web of Science ®Google Scholar
• Brooks AJ, Penn PE. Comparing treatments for dual diagnosis: twelve-step and self-management and recovery training. Am J Drug Alcohol Abuse 2003;29:359–383.
   PubMed Web of Science ®Google Scholar
• Shaner A, Roberts LJ, Eckman TA, Tucker DE, Tsuang JW, Wilkins JN, Mintz J. Monetary reinforcement of abstinence from cocaine among mentally ill patients with cocaine dependence. Psychiatr Serv 1997;48:807–810.
   PubMed Web of Science ®Google Scholar
• Sigmon SC, Higgins ST. Voucher-based contingent reinforcement of marijuana abstinence among individuals with serious mental illness. J Subst Abuse Treat 2006;30:291–295.
   PubMed Web of Science ®Google Scholar
• Baker A, Lewin T, Reichler H, Clancy R, Carr V, Garrett R, Sly K, Devir H, Terry M. Evaluation of a motivational interview for substance use within psychiatric in-patient services. Addiction 2002;97:1329–1337.
   PubMed Web of Science ®Google Scholar
• Hulse GK, Tait RJ. Six-month outcomes associated with a brief alcohol intervention for adult in-patients with psychiatric disorders. Drug Alcohol Rev 2002;21:105–112.
   PubMed Web of Science ®Google Scholar
• Graeber DA, Moyers TB, Griffith G, Guajardo E, Tonigan S. A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders. Community Ment Health J 2003;39:189–202.
   PubMed Web of Science ®Google Scholar
• James W, Preston NJ, Koh G, Spencer C, Kisely SR, Castle DJ. A group intervention which assists patients with dual diagnosis reduce their drug use: a randomized controlled trial. Psychol Med 2004;34:983–990.
   PubMed Web of Science ®Google Scholar
• Martino S, Carroll KM, Nich C, Rounsaville BJ. A randomized controlled pilot study of motivational interviewing for patients with psychotic and drug use disorders. Addiction 2006;101:1479–1492.
   PubMed Web of Science ®Google Scholar
• Barrowclough C, Haddock G, Tarrier N, Lewis S, Moring J, O’Brien R, Schofield N, McGovern J. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry 2001;158:1706–1713.
   PubMed Web of Science ®Google Scholar
• Haddock G, Barrowclough C, Tarrier N, Moring J, O’Brien R, Schofield N, Quinn J, Palmer S, Davies L, Lowens I, McGovern J, Lewis S. Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-month outcomes of a randomized controlled trial. Br J Psychiatry 2003;183:377–378.
   PubMed Web of Science ®Google Scholar
• Baker A, Bucci S, Lewin TJ, Kay-Lambkin F, Constable PM, Carr VJ. Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders. Br J Psychiatry 2006;188:439–448.
   PubMed Web of Science ®Google Scholar
• Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y. A randomized clinical trial of a new behavioral intervention for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry 2006;63:426–432.
   PubMed Web of Science ®Google Scholar
• Barrowclough C, Haddock G, Wykes T, Beardmore R, Conrod P, Craig T, Davies L, Dunn G, Eisner E, Lewis S, Moring J, Steel C, Tarrier N. Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. BMJ 2010;341:c6325. doi: 10.1136/bmj.c6325.
   PubMed Web of Science ®Google Scholar
• Mueser KT, Glynn SM, Cather C, Xie H, Zarate R, Smith LF, Clark RE, Gottlieb JD, Wolfe R, Feldman J. A randomized controlled trial of family intervention for co-occurring substance use and severe psychiatricdisorders. Schizophr Bull 2013;39:658–672. doi: 10.1093/schbul/sbr203.
   PubMed Web of Science ®Google Scholar
• Hjorthoj CR, Fohlmann A, Larsen AM, Gluud C, Arendt M, Mordentoft M. Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the capopus randomized trial. Psychol Med 2013; 43:1499–1510. doi:10.1017/S0033291712002255.
   PubMed Web of Science ®Google Scholar
• Eack SM, Hogarty SS, Greenwald DP, Litschge MY, McKnight SA, Bangalore SS, Pogue-Geile MF, Keshavan MS, Cornelius JR. Cognitive Enhancement Therapy in substance misusing schizophrenia: results of an 18-month feasibility trial. Schizophr Res 2015;161:478–483. doi:10.1016/j.schres.2014.11.017.
   PubMed Web of Science ®Google Scholar
• Milner KK, Barry KL, Blow FC, Welsh D. Brief interventions for patients presenting to the Psychiatric Emergency Service (PES) with major mental illnesses and at-risk drinking. Community Ment Health J 2010; 46:149–155. doi: 10.1007/s10597-009-9182-y.
   PubMed Web of Science ®Google Scholar
• Wojtalik JA, Hogarty SS, Cornelius JR, Phillips ML, Keshavan MS, Newhill CE, Eack SM. Cognitive Enhancement Therapy improves frontolimbic regulation of emotion in alcohol and/or cannabis misusing Schizophrenia: a preliminary study. Front Psychiatry 2016;6:186. doi: 10.3389/fpsyt.2015.00186.
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophr Bull 2010;36:71–93
   Google Scholar
• Zeidonis DM, Trudeau K. Motivation to quit using substances among individuals with schizophrenia: implications for a motivation-based treatment model. Schizophr Bull 1997;23:229–238.
   PubMed Web of Science ®Google Scholar
• Babor TF, McRee BG, Kassebaum PA, Grimaldi PL, Ahmed K, Bray J. Screening, Brief Intervention, and Referral to Treatment (SBIRT): toward a public health approach to the management of substance abuse. Subst Abus 2007;28:7–30.
   PubMedGoogle Scholar
• American Public Health Association and Education Development Center, Inc. Alcohol screening and brief intervention: a guide for public health practitioners. Washington DC: National Highway Traffic Safety Administration, U.S. Department of Transportation.
   Google Scholar
• Carey KB, Purnine DM, Maisto SA, Carey MP. Enhancing readiness-to-change substance abuse in persons with schizophrenia. A four-sessionmotivation-based intervention. Behav Modif 2001;25:331–384.
   Google Scholar
• Graham HL, Copello A, Griffith E, Freemantle N, McCrone P, Clarke L, Walsh K, Stefanidou CA, Rana A, Birchwood, M. Pilot randomized trial of a brief intervention for comorbid substance misuse in psychiatric in-patient settings. Acta Psychiatr Scand 2015; Nov 21 [Epub ahead of print]. doi: 10.1111/acps.12530.
   PubMed Web of Science ®Google Scholar
• Steinberg ML, Ziedonis DM, Krejci JA, Brandon TH. Motivational interviewing with personalized feedback: a brief intervention for motivating smokers with schizophrenia to seek treatment for tobacco dependence. J Consult Clin Psychol 2004;72:723–728.
   PubMed Web of Science ®Google Scholar
• Lucksted A, McFarlane W, Downing D, Dixon L. Recent developments n family psychoeducation as an evidence-based practice. J Marital Fam Ther 2012;38:101–121. doi: 10.1111/j.1752-0606.2011.00256.x.
   PubMed Web of Science ®Google Scholar
• Gottlieb JD, Mueser KT, Glynn SM. Family therapy for schizophrenia: co-occurring psychotic and substance use disorders. J Clin Psychol 2012;68:490–501. doi:10.1002/jclp.21852.
   PubMed Web of Science ®Google Scholar
• Clark RE. Family support and substance use outcomes for persons with mental illness and substance use disorders. Schizophr Bull 2001;27:93–101.
   PubMed Web of Science ®Google Scholar
• Fischer Ep, McSweeney JC, Pyne JM, Williams DK, Naylor AJ, Blow FC, Owen RR. Influence of family involvement and substance use on sustained utilization of services for schizophrenia. Psychiatr Serv 2008;59:902–908.
   PubMed Web of Science ®Google Scholar
• Cleary M, Walter G, Hunt GE, Clancy R, Horsfall J. Promoting dual diagnosis awareness in everyday clinical practice. J Psychosoc Nurs Ment Health Serv 2008;46:43–49.
   PubMed Web of Science ®Google Scholar
• Mueser KT, Gingerich, S. Treatment of co-occurring psychotic and substance use disorders. Soc Work Public Health 2013;28:424–439. doi:10.1080/19371918.2013.774676.
   PubMed Web of Science ®Google Scholar
• Drake RE, Essock SM, Shaner A, Carey KB, Minkoff K, Kola L, Lynde D, Osher FC, Clark RE, Rickards L. Implementing dual diagnosis services for clients with severe mental illness. Psychiatr Serv 2001;52:469–476.
   PubMed Web of Science ®Google Scholar
• Graham HL. Implementing integrated treatment for co-existing substance use and severe mental health problems in assertive outreach teams: training issues. Drug Alcohol Rev 2004; 23:463–470.
   PubMed Web of Science ®Google Scholar
• Hunt GE, Siegfried N, Morley K, Sitharthan T, Cleary M. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev 2013;10: CD001088. doi: 10.1002/14651858.CD001088.pub3.
   Web of Science ®Google Scholar
• Bennett ME, Wilson AL, Genderson M, Saperstein AM. Smoking Cessation in People with Schizophrenia. Current Drug Abuse Rev 2013;6:180–190.
   PubMedGoogle Scholar
• Bennett ME. Assessment of substance use and substance use disorders in schizophrenia. Clin Schizophr Relat Psychoses 2009;3:50–63.
   Google Scholar
• Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, Montoya I, Parks J, Weiss RD. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 2005;11:315–339.
   PubMedGoogle Scholar